用于慢性粒细胞性白血病(以下简称“慢粒”)的化疗药物,迄今已有10余种之多,但一般认为马利兰仍是诸药中的首选药物,其主要优点是缓解率高,疗效快,使用方便。但亦有其缺点,如缓解期短,一般仅为1～2月至年余。如在病人获得病情缓解后继以该药长期维持治疗,在部分病人中可引起皮肤色素沉着、消化道症状、晶体混浊、肺纤维化或诱发急性变,约有5％的患者可死于骨髓抑制,女性患者常引起闭经等。根据马利兰的上述特点,我们考虑应发 Chemotherapy drugs for chronic myeloid leukemia (hereinafter referred to as “CML”), so far there are more than 10 species, but is generally considered Maryland is the drug of choice, its main advantage is the high remission rate, efficacy Fast, easy to use. But there are also disadvantages, such as short response time, usually only 1 to 2 months to more than a year. Such as the patient’s condition was alleviated, followed by the drug long-term maintenance treatment, in some patients can cause skin pigmentation, gastrointestinal symptoms, crystal opacity, pulmonary fibrosis or acute exacerbation, about 5% of patients can die of bone marrow suppression , Female patients often cause amenorrhea and so on. According to Maryland’s above characteristics, we consider should be made